The road to IND isn’t always easy. Balancing speed, risk, and future needs is a challenge. Join Paul Jorjorian, Vice President and General Manager, Thermo Fisher Scientific, to learn how you can take your molecule from discovery through to FiH trials, balancing risk and accelerated timelines while ensuring a stable foundation for future scale-up and commercialization.

We’ll discuss:

  • Why getting to IND as quickly as possible is so critical, and the common pitfalls often experienced
  • How integrated solutions can optimize and speed up the entire DNA to IND workflow and why they’re an effective way to go from an R&D lab to the clinic
  • What actions and strategies accelerate timelines without introducing risks that may jeopardize IND filing and delay time to clinic and market

Featured Speaker

Paul Jorjorian

Vice President and General Manager, Biologics

Thermo Fisher Scientific

As the VP of biologics at Thermo Fisher Scientific, Paul oversees global biologics drug substance manufacturing and development. In his career Paul has developed, transferred or manufactured over 75 biotherapeutic proteins at various clinical phases, including multiple commercial products. His experience includes business strategy development, operations management, technology transfer, process development, process characterization and process validation. Paul holds a B.S. in Chemical Engineering and Management from Purdue University, and a Masters in Chemical Engineering from Cornell University.

Date:  Monday, June 28, 2021
Time:  1pm ET / 10am PT
Duration:  1 Hour

Register now for this webinar